MedTrace Logo

A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer

NCT01801904 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-03-24

No results posted yet for this study

Summary

The purpose of this study is to assess if panitumumab is active enough to warrant comparative studies in patients with metastatic colorectal cancer that has progressed after treatment with cetuximab.

Conditions

Interventions

DRUG

Panitumumab

6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity

Sponsors & Collaborators

  • Azienda Ospedaliera G. Rummo

    collaborator UNKNOWN

  • National Cancer Institute, Naples

    lead OTHER

Principal Investigators

  • Bruno Daniele, M.D. · Azienda Sanitaria Rummo, Benevento, Division of Medical Oncology

  • Francesco Perrone, M.D., Ph.D · National Cancer Institute Naples, Italy; Director Clinical Trials Unit

  • Ciro Gallo, M.D., Ph.D · Second University of Naples, Italy; Chair of Medical Statistics

  • Antonio Gasbarrini, M.D. · Università Cattolica del S. Cuore, Policlinico Gemelli, Roma

  • Giacomo Carteni', M.D. · Ospedale Antonio Cardarelli, Napoli

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01801904 on ClinicalTrials.gov